Intravesical Evans Strain BCG Therapy: Quantitative Immunohistochemical Analysis of the Immune Response within the Bladder Wall

Lamm, D. L.: BCG immunotherapy in bladder cancer. In: 1987 Urology Annual. Appleton and Lange, Norwalk, Connecticut/Los Altos, California, pp. 67-86, 1987. Herr, 1988, Bacillus Calmette-Guérin alters the progression of superficial bladder cancer, J. Clin. Oncol., 6, 1450, 10.1200/JCO.1988.6.9.1450 Bast, 1974, BCG and cancer (2 parts), N. Eng. J. Med., 290, 1413, 10.1056/NEJM197406202902506 Davies, 1982, Bacillus Calmette Guerin as an anti-tumour agent. The interaction with cells of the mammalian immune system, Biochim. Biophys. Acta., 651, 143 Guy, 1986, Expression of MHC Class II antigen in human B cell leukaemia and non-Hodgkins lymphoma, Br. J. Cancer, 53, 161, 10.1038/bjc.1986.31 Reinherz, 1982, The characterization and function of human immunoregulatory T lymphocyte subsets, Pharmacol. Rev., 34, 17 Ratliff, 1987, Requirement of a thymus dependent immune response for BCG mediated antitumour activity, J. Urol., 137, 155, 10.1016/S0022-5347(17)43909-7 Peuchmaur, 1989, Analysis of mucosal bladder subpopulations in patients treated with intravesical Bacillus-Calmette-Guerin, Urol. Res., 17, 299, 10.1007/BF00262987 Bohle, 1989, Effects of local Bacillus Calmette Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall, J. Urol., 144, 53, 10.1016/S0022-5347(17)39365-5 Knapp, 1989, Towards a better definition of human leucocyte surface molecules, Immunology Today, 10, 253, 10.1016/0167-5699(89)90135-7 Ratliff, 1986, Inhibition of murine bladder tumour growth by Bacille Calmette-Guérin: lack of a role for natural killer cells. Br, J. Urol., 41, 108 Lage, 1986, Histological parameters and pitfalls in the interpretation of bladder biopsies in Bacillus Calmette-Guérin treatment of superficial bladder cancer, J. Urol., 135, 916, 10.1016/S0022-5347(17)45922-2 Daar, 1984, The detailed distribution of MHC Class II antigens in normal human organs, Transplantation, 38, 293, 10.1097/00007890-198409000-00019 Bottazo, 1983, Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity, Lancet, 11, 1115, 10.1016/S0140-6736(83)90629-3 Mason, 1985, The possible role of Class II Major Histocompatibility Complex Antigens in self tolerance, Scand. J. Immunol., 21, 398, 10.1111/j.1365-3083.1985.tb01824.x Tjernlund, 1987, Amplification of T-cell response to PPD by epidermal cell suspension containing HLA-DR expressing keratinocytes, Scand. J. Immunol., 26, 1, 10.1111/j.1365-3083.1987.tb02227.x Pober, 1983, Lymphocytes recognise human vascular endothelial and dermal fibroblast antigens induced by recombinant immune interferon, Nature, 305, 726, 10.1038/305726a0 Trinchieri, 1985, Immune interferon: a pleiotropic lymphokine with multiple effects, Immunology Today, 6, 131, 10.1016/0167-5699(85)90080-5 Prescott, 1990, Radioimmunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy, J. Urol., 144, 1248, 10.1016/S0022-5347(17)39713-6 Hawkyard, 1991, The effects of recombinant interferon-gamma on a panel of human bladder cancer cell lines, J. Urol., 145, 1078, 10.1016/S0022-5347(17)38538-5